Document Detail

Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma.
MedLine Citation:
PMID:  23155224     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: The objective of this article was to review randomized clinical trials (RCTs) utilizing pre- and postoperative treatment modalities for esophageal squamous cell carcinoma (ESCC).
MATERIALS AND METHODS: A computerized (MEDLINE) and manual search was performed to identify articles published on this topic between 1984 and 2012.
RESULTS: We identified a total of 49 published RCTs, which included a total of 8,785 patients with ESCC. Treatment modalities consisted of pre- (n=38) and postoperative (n=11) chemo-, radio- and chemoradiotherapy. While both preoperative chemotherapy and chemoradiotherapy apparently improve R0 resection, they often result in substantial postoperative morbidity and mortality. Only for preoperative chemoradiotherapy does there seem to be a significant benefit in overall survival.
CONCLUSION: R0 resection remains the only curative therapy for patients with ESCC. While preoperative chemoradiotherapy may improve overall survival, there is still the need for well-designed RCTs, which should include a homogeneous patient collective, to clarify the question of definitive benefit.
Christiane M R Thallinger; Barbara Kiesewetter; Markus Raderer; Michael Hejna
Related Documents :
9197214 - Idiopathic giant-cell myocarditis--natural history and treatment. multicenter giant cel...
8570074 - Which treatment for which patient in the future? possible modifications in capd.
17804144 - Who survives from out-of-hospital pulseless electrical activity?
7774214 - Long-term survival after intensive care unit admission with sepsis.
10927144 - Can p53 alterations be used to predict tumour response to pre-operative chemo-radiother...
24459664 - Pre-clinical evaluation of rhdl encapsulated retinoids for the treatment of neuroblastoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  4609-27     Citation Subset:  IM    
Department of Internal Medicine I, Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone...
Next Document:  Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC.